These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 23494772

  • 1. Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
    Baeten JM, Grant R.
    Curr HIV/AIDS Rep; 2013 Jun; 10(2):142-51. PubMed ID: 23494772
    [Abstract] [Full Text] [Related]

  • 2. Oral antiretroviral chemoprophylaxis: current status.
    Baeten J, Celum C.
    Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
    [Abstract] [Full Text] [Related]

  • 3. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Baeten JM, Haberer JE, Liu AY, Sista N.
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
    [Abstract] [Full Text] [Related]

  • 4. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
    Krakower D, Mayer KH.
    Ann Intern Med; 2012 Oct 02; 157(7):490-7. PubMed ID: 22821365
    [Abstract] [Full Text] [Related]

  • 5. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM, Mayer KH.
    AIDS Patient Care STDS; 2011 Feb 02; 25(2):63-71. PubMed ID: 21284497
    [Abstract] [Full Text] [Related]

  • 6. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E, Cohan D.
    AIDS; 2013 Jan 02; 27(1):F1-5. PubMed ID: 22914582
    [Abstract] [Full Text] [Related]

  • 7. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR.
    PLoS Med; 2013 Jan 02; 10(9):e1001511. PubMed ID: 24058300
    [Abstract] [Full Text] [Related]

  • 8. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C, Baeten JM.
    Curr Opin Infect Dis; 2012 Feb 02; 25(1):51-7. PubMed ID: 22156901
    [Abstract] [Full Text] [Related]

  • 9. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 10. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.
    Krakower D, Mayer KH.
    Curr HIV/AIDS Rep; 2011 Dec 01; 8(4):241-8. PubMed ID: 22002729
    [Abstract] [Full Text] [Related]

  • 11. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI, Okoromah CA.
    Cochrane Database Syst Rev; 2009 Jan 21; (1):CD007189. PubMed ID: 19160329
    [Abstract] [Full Text] [Related]

  • 12. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.
    J Acquir Immune Defic Syndr; 2013 Jul 21; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [Abstract] [Full Text] [Related]

  • 13. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J, Dufrene SL, Okulicz JF.
    Ann Pharmacother; 2014 Apr 21; 48(4):507-18. PubMed ID: 24473492
    [Abstract] [Full Text] [Related]

  • 14. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis.
    Baeten J, Celum C.
    Annu Rev Med; 2013 Apr 21; 64():219-32. PubMed ID: 23020883
    [Abstract] [Full Text] [Related]

  • 15. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL.
    Drugs; 2013 Mar 21; 73(3):279-91. PubMed ID: 23444256
    [Abstract] [Full Text] [Related]

  • 16. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Priddy FH.
    PLoS One; 2012 Mar 21; 7(4):e33103. PubMed ID: 22511916
    [Abstract] [Full Text] [Related]

  • 17. Antiretroviral chemoprophylaxis: state of evidence and the research agenda.
    Mayer KH.
    Clin Infect Dis; 2014 Jul 21; 59 Suppl 1(Suppl 1):S47-51. PubMed ID: 24926034
    [Abstract] [Full Text] [Related]

  • 18. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
    Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M.
    PLoS One; 2014 Jul 21; 9(1):e83736. PubMed ID: 24421901
    [Abstract] [Full Text] [Related]

  • 19. A perspective on progress and gaps in HIV prevention science.
    Kiser PF, Mesquita PM, Herold BC.
    AIDS Res Hum Retroviruses; 2012 Nov 21; 28(11):1373-8. PubMed ID: 22966871
    [Abstract] [Full Text] [Related]

  • 20. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW.
    AIDS Behav; 2013 Feb 21; 17(2):737-47. PubMed ID: 23065145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.